C-myc和HIF-1α蛋白在预测巨块型宫颈鳞癌新辅助化疗疗效中的作用

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (2181 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the change of C-myc and HIF-1α protein expression after neoadjuvant intra-arterial chemotherapy and explore the role of C-myc and HIF-1α protein in prediction on the response of neoadjuvant intra-arterial chemotherapy in bulky squamous cervical cancer. Methods: Thirty-six patients with stage Ib2 or IIa2 squamous cervical cancer who underwent neoadjuvant intra-arterial chemotherapy, combined cisplatin with 5-fluorouracil and mitomycin, and radical hysterectomy between 2007 and 2012 in Wenzhou Medical University were selected. Western blot was used to detect the specific expression of C-myc and HIF-1α protein. Then, streptavidin peroxidase (SP) immunohistochemical staining was used to detect the cellular localization of C-myc and HIF-1α protein and the difference of the expression of C-myc and HIF-1α protein between before and after neoadjuvant chemotherapy and between chemotherapy-response group and non-response group. Results: ①The total effective rate of neoadjuvant intra-arterial chemotherapy in bulky squamous cervical cancer was 52.7%. ②The expression of C-myc and HIF-1α protein in tumor cells after chemotherapy was significantly lower than that before chemotherapy (P<0.05). ③There was positive correlation between the expression of C-myc protein and HIF-1α protein before chemotherapy. ④The expression of C-myc and HIF-1α protein in chemotherapy-response group before chemotherapy was significantly higher than that in non-response group (P<0.05). Conclusion:
The expression of C-myc and HIF-1α protein in bulky squamous cervical cancer may be used as a predictor for response to neoadjuvant intra-arterial chemotherapy.

Key words： C-myc HIF-1α cervical neoplasms neoadjuvant chemotherapy response

Received: 19 August 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Jun
	CHENG Miaomiao
	ZHOU Qingfeng
	WANG Ying
	ZHU Xueqiong.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I12/859

[1]Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis[J]. Eur J Surg Oncol, 2013, 39(2): 115-124.
[2]Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis[J]. J Cancer Res Clin Oncol, 2013, 139(11): 1887-1898.
[3]Honjo S, Ajani JA, Scott AW, et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer[J]. Int J Oncol, 2014, 45(2):567-574.
[4]Li S, Li Y, Hu R, et al. The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells[J]. Oncol Lett, 2013, 5(2): 717-721.
[5]Zou Z, Zhang J, Zhang H, et al. 3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy[J]. J Drug Target, 2014, 22(9): 839-848.
[6]Li T, Tang L, Bian D, et al. Detection of hTERC and c-MYC genes in cervical epithelial exfoliated cells for cervical cancer screening [J]. Int J Mol Med, 2014, 33(5): 1289-1297.
[7]Liao LM, Sun XY, Liu AW, et al. Low expression of long noncoding XLOC 010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer[J]. Gynecol Oncol, 2014, 133(3): 616-623.
[8]Kasuya K, Tsuchida A, Nagakawa Y, et al. Hypoxia-induc-ible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer[J]. Oncol Rep, 2011, 26(6): 1399-1406.
[9]Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth[J]. Proc Natl Acad Sci USA, 2011, 108(10): 4129-4134.
[10]Zou S, Shen Q, Hua Y, et al. Proteomic identification of neo-adjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervical cancer[J]. Reprod Sci, 2013, 20(11):1356-1364.
[11]吴均, 陈苗苗, 王颖, 等. mTOR-PKM2信号通路与宫颈鳞癌新辅助动脉化疗疗效的相关性研究[J]. 浙江医学, 2014, 36(2): 94-97.
[12]Hatano K, Yamaguchi S, Nimura K, et al. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc[J]. Mol Cancer Res, 2013, 11(9): 1088-1100.
[13]Todorović-Raković N, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. C-myc as a predictive marker for chemotherapy in metastatic breast cancer[J]. Clin Exp Med, 2012, 12(4): 217-223.
[14]唐金芝, 许君艳, 高琨, 等. C-MYC基因在宫颈上皮内瘤变及宫颈癌治疗前后的表达及其与HPV的相关性[J]. 广西医科大学学报, 2014, 31(1): 86-88.
[15]Yim EK, Lee KH, Kim CJ, et al. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells[J]. Int J Gynecol Cancer, 2006, 16(2): 690-697.
[16]Nakamura J, Kitajima Y, Kai K, et al. Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluoro-uracil-based adjuvant chemotherapy in advanced gastric cancer[J]. Oncol Rep, 2009, 22(4): 693-699.
[17]Ishikawa H, Sakurai H, Hasegawa M, et al. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys,2004, 60(2): 513-521.
[18]Nakai H, Watanabe Y, Ueda H, et al. Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer[J]. Cancer Lett, 2007, 251(1): 164-167.